Komori
Dividends4570Immuno-Biological Laboratories Co.,Ltd.Pharmaceuticals

Notice Concerning Dividend of Surplus

The Company has decided to pay a year-end dividend of ¥6 per share for the fiscal year ending March 2026. This is the same as the latest forecast and represents a resumption of dividend payments following no dividend in the previous fiscal year.

Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
6
Yen/share
Wording
Definitive
How definitive the wording is.

Dividend per share

Fiscal year ending March 2026
6YenRevised annual dividend per sharePrevious forecast ¥6, change ¥0(0.0%)
Previous forecastAfter revision

Each vertical step represents one dividend payment, and the total height of the accumulated steps represents the annual dividend for the period. For periods showing only the annual amount, the payment breakdown is not provided, so only the end point is plotted.

Total dividendsTotal amount payable to all shareholdersAmount 55,880 thousand yen
Whether Submission to the General Meeting of Shareholders Is RequiredScheduled to be submitted to the General Meeting of Shareholders
Record date31 March 2026
Effective date26 June 2026

The record date is the cutoff date for determining which persons listed in the shareholder register on that date are entitled to receive dividends.Payments begin on the effective date.

Source of dividendsRetained earningsThe source of dividend payments. Depending on the type of surplus, the dividend may be paid from earned profits or may be closer to a return of capital.
Dividend policy

The Company's basic policy is to enhance returns to shareholders while considering the balance between strengthening its financial position to support sustainable growth and providing continuous and stable returns to shareholders.

Dividend per share
ItemDetails
Dividend per share¥6.00 → ¥6.00(0.0%)
Total dividendsNot disclosed → Amount 55,880 thousand yen
Record date31 March 2026
Effective date26 June 2026
Source of dividendsRetained earnings
Dividend policyThe Company's basic policy is to enhance returns to shareholders while considering the balance between strengthening its financial position to support sustainable growth and providing continuous and stable returns to shareholders.
Whether Submission to the General Meeting of Shareholders Is RequiredScheduled to be submitted to the General Meeting of Shareholders
Fiscal Period CoveredFiscal year ending March 2026
Items this document does not state (4)
Total Annual DividendsPrevious-period results (per share)Breakdown of Regular, Commemorative and Special DividendsPayout ratio

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

After considering the balance between strengthening the Company's financial position to support sustainable growth and providing continuous and stable returns to shareholders, as well as comprehensively reviewing full-year performance and the future business environment, the Company set the year-end dividend at ¥6 per share, as initially forecast.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning Dividend of Surplus | Immuno-Biological Laboratories Co.,Ltd. (4570) timely disclosure | Komori